Amrize Ltd (AMRZ) Stock Analysis
Market Closed
Sector: Basic Materials · Industry: Cement, Hydraulic
Price History
5-Year Weekly Candlestick Chart
Profile
Strong valuation; earnings quality, growth and financial health lag behind.
How is each axis scored?
- Valuation90/100 · Strong
- P/E vs own history (1th pct)25/25
- FCF yield (6.7%)20/25
- P/S (1.8x)25/25
- EV/EBIT (13.5x)20/25
- Growth20/100 · Weak
- Revenue CAGR (n/a)0/25
- Net income CAGR (n/a)0/25
- EPS CAGR 5Y (n/a)0/25
- Fwd implied growth (18.2%)20/25
- Profitability64/100 · Moderate
- ROIC (8.5%)12/25
- ROE (9.0%)12/25
- Net margin (10.0%)20/25
- Operating margin (16.1%)20/25
- Financial Health37/100 · Weak
- Altman Z (1.33)3/25
- Current ratio (1.40)12/25
- Interest coverage (4.6x)10/25
- Net cash / debt (D/A 19%)12/25
- Quality12/100 · Weak
- Piotroski F (0/9)0/25
- Beneish M (n/a)0/25
- FCF conversion (n/a)0/25
- Margin stability (σ 8.1%)12/25
About Amrize Ltd
Amrize is a building solutions company focused exclusively on the North American market. Show more
Amrize earns revenue from the sale of cement, aggregates, ready-mix concrete, asphalt, roofing systems, and other building solutions. The company is organized into two reportable segments: building materials and building envelope. The building materials business consists of Amrize's cement, aggregates, ready-mix concrete, and asphalt operations. The building envelope segment offers advanced roofing and wall systems, including single-ply membranes, insulation, shingles, sheathing, waterproofing, and protective coatings, along with adhesives, tapes, and sealants.
Headquarters: ZUG · Employees: 19,000 · Website ↗
Analyst Consensus
BuyWall Street consensus estimates — not a PMP forecast · Updated Sep 21, 2026
Insider Transactions
Recent SEC Form 4 filings
- BuyOpen market buy · filed 2026-08-31+5 sh2026-08-27
- BuyOpen market buy · filed 2026-08-26+4.2K sh2026-08-26
- BuyOpen market buy · filed 2026-08-26+3.5K sh2026-08-25
- BuyOpen market buy · filed 2026-08-25+1.5K sh2026-08-25
- BuyOpen market buy · filed 2026-08-13+3.0K sh2026-08-12
+3 more recent filings
Key Metrics
Financial snapshot — pillar inputs plus per-share and market context
Valuation
90A+P/E (TTM)18.0xB
Grade B: FairPrice / TTM EPS (own statements) — vs own 1Y history: 17.5x–90.0x · 1st pct
P/FCF—
Price / Free Cash Flow per share (Finnhub). Inverse of FCF yield — negative when FCF is negative
FCF Yield6.7%A
Grade A: ValueTTM FCF / Market Cap — vs own 1Y history: -3.5%–6.8% · highest in history
P/S (TTM)1.79xA
Grade A: CheapPrice / TTM Revenue (own statements) — vs own 1Y history: 1.8x–5.8x · lowest in history
EV/EBIT13.5xB
Grade B: FairEnterprise value / TTM EBIT (D&A not in our data) — capital-structure neutral — vs own 1Y history: 13.3x–55.7x · lowest in history
EV/Sales—
Enterprise Value / TTM Revenue (Finnhub) — capital-structure neutral sales multiple
Forward P/E15.2xB
Grade B: FairPrice / next-year EPS estimate — shows whether the TTM multiple is rich or just front-loading growth
P/B Ratio1.61xA
Grade A: FairPrice to Book Value. Neg. equity = heavy buybacks
PEG Ratio1.38B
Grade B: FairFinnhub PEG — their P/E basis ÷ expected EPS growth. Suppressed when their P/E diverges >2× from our TTM P/E (different basis)
Dividend Yield—
TTM dividend yield (Finnhub) — annual dividends / price. None = no dividend; very high yield can signal distress
Payout Ratio—
Dividends / Net Income (Finnhub) — share of earnings paid out; >90% or negative = unsustainable
Profitability
64BROIC8.5%C
Grade C: AvgNOPAT (EBIT less ~21% tax) / invested capital (equity + debt − cash). Flagship quality metric — durable >15% signals a moat
ROE9.0%D
Grade D: WeakReturn on Equity. Neg. equity = heavy buybacks
ROA5.0%D
Grade D: WeakReturn on Assets (Finnhub) — Net Income / Total Assets; how efficiently assets produce profit
Net Margin10.0%A
Grade A: HighNet Income / Revenue
Operating Margin16.1%C
Grade C: AvgTTM EBIT / TTM Revenue
Gross Margin25.7%D
Grade D: LowGross Profit / Revenue
FCF Margin12.0%C
Grade C: AvgFCF / Revenue
True FCF Margin11.9%C
Grade C: AvgTTM (OCF − CapEx − SBC) / TTM Revenue — SBC treated as a real cost
Financial Health
37DAltman Z-Score1.33D
Grade D: DistressBankruptcy risk. >3 Safe, <1.8 Distress
Current Ratio1.40xC
Grade C: OkCurrent Assets/Liabilities
Quick Ratio1.07xA
Grade A: High(Current Assets − Inventory) / Current Liabilities (Finnhub) — stricter liquidity test, excludes inventory
Interest Coverage4.6xC
Grade C: OkEBIT/Interest. >10 Strong
Debt Repayment3.2yC
Grade C: AvgYears to repay net debt via FCF
Net Debt/EBIT2.4xC
Grade C: MedLeverage. <2x Low, >4x High
Debt/Equity0.44xA
Grade A: LowDebt / Equity: <1 Conservative, >2 Risky. Not meaningful with non-positive equity; shown as unavailable rather than low debt.
Cash / Debt0.19xD
Grade D: ThinCash covers how much of total debt. >1 = could repay all debt from cash
Growth
20ERevenue CAGR—
Compound annual revenue growth (up to 5Y depending on data availability)
Net Income CAGR—
Compound annual net income growth (up to 5Y depending on data availability)
EPS CAGR (5Y)—
Compound annual EPS growth over up to 5Y of per-share earnings (own statements). Null when either endpoint EPS ≤ 0
Forward Growth18.2%C
Grade C: MedImplied 1Y EPS growth from forward P/E vs our TTM EPS. Sparse — only where forward estimates exist
Dilution (5Y)—
Share count change over 5Y
SBC / Net Income1.2%A
Grade A: LowStock-based comp/Net income. >30% = dilution risk
SBC / Revenue0.1%A
Grade A: LowTTM stock-based comp / TTM Revenue
Quality
12EPiotroski F-Score0/9D
Grade D: WeakFinancial strength 0–9. >7 Strong
Beneish M-Score—
Earnings manipulation risk. < -2.22 Safe
FCF Conversion—
FCF / Net Income
Margin Stability8.1%C
Grade C: AvgEBIT margin std deviation. Lower = stable
Capex / Revenue6.7%C
Grade C: AvgTTM CapEx / TTM Revenue — high % = capital-hungry business
Asset Turnover0.49xD
Grade D: LowRevenue / Total Assets (Finnhub) — how efficiently the asset base generates sales
Per Share
EPS (TTM)$2.14
Own TTM net income / shares — same earnings basis as P/E
Cash / Share$3.48
Cash & short-term investments per share (Finnhub)
Book Value / Share$23.40
Shareholders' equity per share (Finnhub). Negative = accumulated losses / heavy buybacks
Balance Sheet
Total Debt$5.71B
Total debt obligations (short + long term)
Cash & Equiv.$1.10B
Cash and short-term investments
Net Debt$4.61B
Total Debt minus Cash. Negative = Net Cash position
Total Equity$13.09B
Shareholders' equity (book value)
Asset / Liability2.17xA
Grade A: SolidTotal Assets / Total Liabilities
Market
Market Cap$21.11B
Current Market Capitalization
Beta0.90B
Grade B: MarketPrice sensitivity vs the market (Finnhub) — 1.0 moves with market, >1.2 amplifies swings
Takeaway
AMRZ predstavuje vysoko rizikovú špekuláciu, kde atraktívne ocenenie a solídny 6,7 % FCF výnos narážajú na vážne riziko insolvencie vyjadrené kritickým Altman Z-skóre 1,33.
Takes ~3.2 years to repay net debt from free cash flow. · Current P/E of 18.0x sits at the 1st percentile of its historical range.
How grades work: each metric is graded A–D against fixed thresholds (tap a row for the meaning). Card grades map the pillar score to A+–E — a card grade is that pillar's own score, not an average of the rows shown.
Financials as of Mar 2026 · Ratio snapshot Sep 22, 2026
Key Insights: Amrize Ltd (AMRZ)
Composite verdict for Amrize Ltd: AMRZ predstavuje vysoko rizikovú špekuláciu, kde atraktívne ocenenie a solídny 6,7 % FCF výnos narážajú na vážne riziko insolvencie vyjadrené kritickým Altman Z-skóre 1,33.. Amrize Ltd meets only 0 of 9 Piotroski F-Score criteria — a sign of weak underlying fundamentals. Altman Z-Score of 1.33 is below the 1.81 distress threshold — an elevated financial-risk flag.
- Takes ~3.2 years to repay net debt from free cash flow.
- At a valuation score of 90/100, AMRZ trades near the cheapest end of its own historical range (P/E 18.0).
See how AMRZ ranks on the Capex Tracker — top 50 capital spenders compared.
No significant market moves for AMRZ in the last 30 days.
See AMRZ move history →Frequently Asked Questions about AMRZ
Is AMRZ stock a buy right now?
PreMarketPrice's quantitative model rates Amrize Ltd's financial health at 37/100 — AMRZ predstavuje vysoko rizikovú špekuláciu, kde atraktívne ocenenie a solídny 6,7 % FCF výnos narážajú na vážne riziko insolvencie vyjadrené kritickým Altman Z-skóre 1,33.. This is a data-driven snapshot of fundamentals, not investment advice.
Is AMRZ stock overvalued?
Amrize Ltd trades at a trailing P/E of 18.0 and our valuation score rates it 90/100 (higher = cheaper vs. its own history). See the Valuation History and Key Metrics sections for forward P/E, EV/EBITDA and PEG context.
When does Amrize Ltd report earnings?
No confirmed earnings date is currently scheduled for AMRZ. The Earnings section lists recent reports and updates as dates are announced.
What sector does Amrize Ltd operate in?
Amrize Ltd operates in the Basic Materials sector, within the Cement, Hydraulic industry. The Related Stocks section lists sector peers for comparison.
What does Amrize Ltd do?
Amrize is a building solutions company focused exclusively on the North American market.
About Amrize Ltd (AMRZ) Stock
Amrize Ltd (AMRZ) is a US-listed stock operating in the Basic Materials sector, specifically the Cement, Hydraulic industry. Real-time pricing data for Amrize Ltd is available on this page with a market capitalization of $21.1 billion. The financial health score for AMRZ is 37/100, which indicates weak financial strength based on profitability, leverage, liquidity, and growth metrics. This page provides real-time pre-market pricing, earnings calendar, financial health analysis, and valuation metrics for AMRZ stock.
AMRZ Stock Analysis & Key Metrics
On PreMarketPrice, you can track Amrize Ltd (AMRZ) across multiple dimensions:
- Pre-market price & movement: Real-time AMRZ stock price with percentage change, updated continuously during pre-market and regular trading hours.
- Valuation & P/E history: Historical P/E, P/S, and P/B ratios for AMRZ with trend analysis and normalized valuation multiples.
- Financial statements: Revenue, net income, assets, liabilities, and equity for Amrize Ltd across multiple reporting periods.
- Financial health score: A composite score of 37/100 based on Altman Z-Score, Piotroski F-Score, profitability, and leverage metrics for AMRZ.
- Sector peers: Compare AMRZ against 10 other basic materials stocks on key financial metrics.
Is AMRZ a Good Stock to Buy?
This page provides data-driven analysis to help you evaluate Amrize Ltd (AMRZ) as an investment. The financial health score of 37/100 suggests weak financial fundamentals. Valuation metrics show whether the stock is trading above or below its historical average.However, this is not financial advice — always do your own research before investing.
Data on this page is sourced from real-time market feeds, Polygon.io, and Finnhub.Amrize Ltd (AMRZ) trades on NYSE/NASDAQ. Pre-market trading occurs 4:00 AM – 9:30 AM ET. Regular market hours are 9:30 AM – 4:00 PM ET.